Products
Eftrenonacog Alfa Biosimilar Fusion Protein (Factor IX) for Research
Pre-Made Eftrenonacog Alfa Biosimilar, Fusion Protein targeting F9 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Eftrenonacog alfa is a long-acting recombinant fusion protein used in the treatment of hemophilia B. It is comprised of a single molecule of human factor IX (FIX) covalently linked to the constant region (Fc) domain of human IgG1. It serves as a replacement therapy to increase the plasma levels of factor IX thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-830-1mg | 1mg | 3090 |
| GMP-Bios-INN-830-10mg | 10mg | |
| GMP-Bios-INN-830-100mg | 100mg | |
| GMP-Bios-INN-830-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Eftrenonacog Alfa Biosimilar, Fusion Protein targeting F9 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8 |
| INN Name | Eftrenonacog Alfa |
| Target | F9 |
| Format | Fusion Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | Fusion - [F9 (coagulation factor 9, coagulation factor IX) recombinant]1 - IGHG1 Fc (Fragment constant) |
| VD LC | Fusion - [F9 (coagulation factor 9, coagulation factor IX) recombinant]1 - IGHG1 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Biogen, Inc. (Cambridge MA USA) / SOBI (Swedish Orphan Biovitrum AB) (Stockholm Sweden) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - F9
1. Protein Coagulation factor IX
2. Gene F9
3. Organism Homo sapiens (Human)
Function
Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca2+ ions, phospholipids, and factor VIIIa.
Miscellaneous
In 1952, one of the earliest researchers of the disease, Dr. R.G. Macfarlane used the patient's surname, Christmas, to refer to the disease and also to refer to the clotting factor which he called the 'Christmas Factor' At the time Stephen Christmas was a 5-year-old boy. He died in 1993 at the age of 46 from acquired immunodeficiency syndrome contracted through treatment with blood products.
Catalytic activity
Selective cleavage of Arg-|-Ile bond in factor X to form factor Xa.
